Dual Bronchodilation By Once Daily Fixed Dose Combined Indacaterol And Glycopyrronium, New Era For Treatment In Moderate To Severe COPD

Authors

  • Md Kazi Shihab Uddin Assistant Professor, Department of Medicine, KYAMCH, Enayetpur, Sirajganj

DOI:

https://doi.org/10.3329/kyamcj.v7i2.33842

Keywords:

QVA149- Code name used for dual bronchodilah, COPD-Chronic obstructive pulmonary disease, LABA-long-acting bronchial agonist, LAMA-long-acting muscarinic antagonist, GOLD-Global Initiative for chronic obstructive lung Disease, SAC-self assessment

Abstract

Original Article- Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE study (Ref: ERJ Express. Published on October 31, 2013 as doi: 10.1183/09031936.00124013)

Abstract: The effect of a dual bronchodilator (QVA149) was evaluated combining Indacaterol and Glycopyrronium, on direct patient-reported dyspnoea in moderate-to severe COPD. In this multicentre, blinded, double-dummy, three-period crossover study, once-daily QVA149 provided superior improvements in patientreported dyspnoea and lung function versus placebo and tiotropium. These benefits were associated with improvements in other symptoms and reduced use of rescue medication.

KYAMC Journal Vol. 7, No.-2, Jan 2017, Page 804-805

Downloads

Download data is not yet available.
Abstract
12
PDF
13

Author Biography

Md Kazi Shihab Uddin, Assistant Professor, Department of Medicine, KYAMCH, Enayetpur, Sirajganj



Downloads

Published

2017-08-31

How to Cite

Uddin, M. K. S. (2017). Dual Bronchodilation By Once Daily Fixed Dose Combined Indacaterol And Glycopyrronium, New Era For Treatment In Moderate To Severe COPD. KYAMC Journal, 7(2), 804–805. https://doi.org/10.3329/kyamcj.v7i2.33842

Issue

Vol. 7 No. 2 (2017)

Section

Review Articles